Effects of linear accelerator X-rays on red blood cells collected during cancer surgery
A Multi-dimensional Evaluation of the Effects of Linear Accelerator X-ray Irradiation on the Morphology, Mechanical Properties and Functions of Red Blood Cells
This project will test whether X-rays from a linear accelerator change the structure and function of red blood cells collected from adults undergoing cancer surgery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University Academic / other |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Trial ID | NCT07416045 on ClinicalTrials.gov |
What this trial studies
Researchers will collect red blood cells recovered during elective oncologic surgeries and expose them to different doses of X-rays delivered by a clinical linear accelerator. They will use atomic force microscopy, microfluidic chips, biochemical assays, microtubule suction techniques, and cross-scale numerical simulation to measure membrane ultrastructure, deformability, flow behavior, and oxygen-carrying capacity. The study will map dose–effect relationships between irradiation dose and measures of red blood cell damage. Findings aim to provide preclinical evidence to guide safe irradiation processing of autologous blood for intraoperative salvage.
Who should consider this trial
Good fit: Adults aged 18–65 scheduled for elective malignant tumor surgery with an expected blood loss of ≥500 mL are ideal candidates.
Not a fit: Patients with preexisting red blood cell production disorders or hemolytic conditions (for example, aplastic anemia, thalassemia, PNH, or G6PD deficiency) are unlikely to benefit and are excluded.
Why it matters
Potential benefit: If successful, this could identify safe X-ray doses for treating salvaged autologous blood and lower the risk of transfusing damaged red blood cells during cancer surgery.
How similar studies have performed: While irradiation is used elsewhere for blood product safety, applying linear accelerator X-rays specifically to intraoperative autologous red blood cells is relatively novel and lacks extensive prior clinical data.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients scheduled for elective surgery for malignant tumors * Age: 18 - 65 years old * It is estimated that the surgical bleeding will be greater than or equal to 500 milliliters. Exclusion Criteria: * Disorders of red blood cell production (such as aplastic anemia, megaloblastic anemia, iron deficiency anemia, leukemia, myelofibrosis, etc.) * Diseases caused by increased destruction of red blood cells (abnormalities in red blood cell membranes such as hereditary spherocytosis and paroxysmal nocturnal hemoglobinuria; abnormalities in hemoglobin such as thalassemia; abnormalities in red blood cell-related enzymes such as glucose-6-phosphate dehydrogenase deficiency, etc.)
Where this trial is running
Hangzhou, Zhejiang
- The Second Affiliated Hospital, School of Medicine, Zhejiang University,anesthesiology department, — Hangzhou, Zhejiang, China (Recruiting)
Study contacts
- Study coordinator: Fengjiang Zhang
- Email: zrzfj@zju.edu.cn
- Phone: +8613858007629
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.